Los Angeles, California 90048


The purpose of this study is to determine whether cognitive rehabilitation or psychoeducation impacts medication adherence in HIV-1 seropositive individuals.

Study summary:

Although antiretroviral therapy (ART) has proven extremely effective in the treatment of HIV and AIDS, the ability to effectively combat the disease is inconsequential when individuals do not take their medication as prescribed and do not attend their scheduled medical appointments. Non-adherence to effective ART and medical visits is widespread in the United States, especially among ethnic minorities. A recent study indicated that patients who miss a medical appointment in the first year of an HIV diagnosis show over twice the mortality rate of patients who attended all visits. This study is developed to investigate the relationship between HIV Associated Neurocognitive Disorder (HAND) and adherence to HIV treatment among traditionally marginalized populations. Participants will be administered a brief neuropsychiatric screener. Participants will be randomly enrolled one of two cognitive rehabilitation programs so they may learn compensatory cognitive strategies to remain treatment adherent, or they will be receive psychoeducation concerning the importance of taking their medications and regularly attending medical appointments. Participants will be tracked and followed-up with regarding their treatment adherence in regular intervals over the course of 6 months.


Inclusion Criteria: - Adult, age 18 and older. - Able and willing to provide written informed consent. - Diagnosed as HIV-seropositive by licensed enzyme-linked immunoabsorbent assay (ELISA) or HIV-seropositive by Western blot (WB). - Diagnosed as HIV seropositive within the last two years. - Willing and able to provide adequate information for locator purposes. Exclusion Criteria: - Under the age of 18. - Have ever sustained a traumatic brain injury. - Have an obvious psychological/psychiatric disorder that would invalidate the informed consent process, or otherwise contraindicate participation in the study. - Have a learning disability where they cannot read or write pass the third grade level. - Have an active substance dependence diagnosis.



Primary Contact:

Principal Investigator
Kimberly Smith, PsyD
Cedars-Sinai Medical Center

Kimberly L Smith, PsyD
Phone: 310-248-7682
Email: kimberly.smith2@cshs.org

Backup Contact:

Email: enrique.lopez@cshs.org
Enrique Lopez, PsyD
Phone: 310-423-4555

Location Contact:

Los Angeles, California 90048
United States

Kimberly L Smith, PsyD
Phone: 310-248-6782
Email: kimberly.smith2@cshs.org

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: October 18, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.